Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain.

Autor: Monte-Boquet E; Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia, España. Electronic address: monte_emi@gva.es., Florez Á; Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España., Alcaín Martínez GJ; Unidad de Gestión Clínica de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Málaga, España., Sellas A; Servicio de Reumatología, Hospital Universitari Arnau de Vilanova, Lleida, España.
Jazyk: angličtina
Zdroj: Reumatologia clinica [Reumatol Clin (Engl Ed)] 2023 Oct; Vol. 19 (8), pp. 446-454.
DOI: 10.1016/j.reumae.2022.12.004
Abstrakt: Objective: To improve knowledge about biosimilar medicines and to generate a consensus framework on their use.
Methods: Qualitative study. A multidisciplinary group of experts in biosimilar medicines was established (1dermatologist, 1hospital pharmacist, 1rheumatologist, and 1gastroenterologist) who defined the sections and topics of the document. A narrative literature review was performed in Medline to identify articles on biosimilar medicines. Systematic reviews, controlled, pre-clinical, clinical, and real-life studies were selected. Based on the results of the review, several general principles and recommendations were generated. The level of agreement was tested in a Delphi that was extended to 66 health professionals who voted from 1 (totally disagree) to 10 (totally agree). Agreement was defined if at least 70% of the participants voted ≥7.
Results: The literature review included 555 articles. A total of 10 general principles and recommendations were voted upon. All reached the level of agreement established. The document includes data on the main characteristics of biosimilar medicines (definition, development, approval, indication extrapolation, interchangeability, financing, and traceability); published evidence (biosimilarity, efficacy, effectiveness, safety, immunogenicity, efficiency, switch); barriers and facilitators to its use; and data on information for patients.
Conclusions: Authorized biosimilar medicines meet all the characteristics of quality, efficacy, and safety. They also significantly help improve patient access to biological therapies and contribute to health system sustainability.
(Copyright © 2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: